FIBROVEIN

This brand name is authorized in Estonia, France, Hong Kong SAR China, Malta, New Zealand, Poland, Romania, UK.

Active ingredients

The drug FIBROVEIN contains one active pharmaceutical ingredient (API):

1	Sodium tetradecyl sulfate UNII Q1SUG5KBD6 - SODIUM TETRADECYL SULFATE
	Sodium tetradecyl sulfate is a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.
	Read more about Sodium tetradecyl sulfate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FIBROVEIN Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C05BB04	Sodium tetradecyl sulfate	C Cardiovascular system → C05 Vasoprotectives → C05B Antivaricose therapy → C05BB Sclerosing agents for local injection
Discover more medicines within C05BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1820236
FR	Base de données publique des médicaments	60021771, 62685543, 68264234, 69320675
GB	Medicines & Healthcare Products Regulatory Agency	227981, 227983, 227985, 227987, 227989
HK	Department of Health Drug Office	62315, 62316, 62317, 62318
MT	Medicines Authority	AA565/09403, AA770/16401, AA770/16402
NZ	Medicines and Medical Devices Safety Authority	1253, 1254, 1255, 1256
PL	Rejestru Produktów Leczniczych	100375464, 100375470, 100375487, 100375493
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67003001, W67003002, W67003003, W67004001, W67005001, W67006001, W67006002, W67006003, W67006004